about
New technologies in predicting, preventing and controlling emerging infectious diseasesSyphilis on the rise: A prolonged syphilis outbreak among HIV-infected patients in Northern Greece.Is the mortality rate for septic shock really decreasing?Immunomodulatory therapy for sepsis: an update.The complex pathogenesis of bacteremia: from antimicrobial clearance mechanisms to the genetic background of the hostThe beginning of personalized medicine in sepsis: small steps to a bright future.Pre-Exposure Prophylaxis for HIV: Evidence and Perspectives.The kinetics of T regulatory cells in shock: beyond sepsis.NK and NKT Cell Depletion Alters the Outcome of Experimental Pneumococcal Pneumonia: Relationship with Regulation of Interferon-γ Production.Predictors of humoral response to recommended vaccines in HIV-infected adults.Host immune response in sepsis due to ventilator-associated pneumonia: how is it different?Estrogen receptor beta agonism increases survival in experimentally induced sepsis and ameliorates the genomic sepsis signature: a pharmacogenomic study.Personalized medicine in sepsis: the coming of age.In vivo natural killer and natural killer T-cell depletion affects mortality in a murine pneumococcal pneumonia sepsis model.Clostridium difficile infections in a university hospital in Greece are mainly associated with PCR ribotypes 017 and 126.Regulation of sepsis-induced IFNγ upon natural killer cell or natural killer T cell depletion in vivo.Influenza Virus-Host Co-evolution. A Predator-Prey Relationship?Specific antibody to Cryptococcus neoformans glucurunoxylomannan antagonizes antifungal drug action against cryptococcal biofilms in vitroA monoclonal antibody against RAGE alters gene expression and is protective in experimental models of sepsis and pneumococcal pneumoniaAntimicrobial Resistance in Bacteria: Mechanisms, Evolution, and PersistenceMicrobiology of acute bacterial skin and skin-structure infections in Greece: A proposed clinical prediction score for the causative pathogen
P50
Q28081855-6EC317AC-7D3D-4801-99D3-6618C9536D41Q37246658-7A3CEB18-B0A5-45FB-88E3-4D6ACE1CA744Q37267168-1D7A2710-2804-4932-AD72-8624DD799E7BQ37949639-2D6AB4E5-A267-40D6-9580-6DB5ED345B85Q38143425-71523DD1-4FD3-4A64-9BAC-926E0F888C20Q38191987-592F5A5F-DCCC-4C31-AB16-9189C1145A1CQ38737993-C7C947AD-0B50-45DC-B3D8-DA35F6415C3EQ41128947-9D36F1DA-0E85-442F-90B3-0D652FDECD54Q41138405-9535192D-FDDE-493A-8924-706B932C94DEQ41936560-DD1C4C17-4B29-4387-A25C-EE7EE68F3DA1Q42185763-B8E9A33A-65C4-4FBD-867D-019EEB83EC3AQ43141773-CE7ED594-8FC6-4F6C-AFC4-B5601DDDFE38Q44620260-BCDE688B-1920-4108-B3B5-C7ADD703DAE2Q45929780-7BC9FACA-CB46-4DEA-81DB-3065C2C7C984Q47229973-92BD2977-8CBC-4D1E-A9FF-89D5F2D7D2B3Q50154057-A38761D2-36B8-4F89-8BDD-30E65D939853Q56998080-E461C2D5-3BF3-43F9-9675-6F17F5E082ACQ79738881-DEB631C5-566D-4B8B-A3CA-A6D3711E5C52Q83288802-C2D38DE1-B012-42D7-B9A6-0E3281ED4FBFQ90976082-71ECF6C3-50B3-482F-9260-E7C82557C8C5Q93075474-07F6BDBC-A1DE-40CA-9E9A-061F0594D1C5
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Eirini Christaki
@ast
Eirini Christaki
@en
Eirini Christaki
@es
Eirini Christaki
@nl
Eirini Christaki
@sl
type
label
Eirini Christaki
@ast
Eirini Christaki
@en
Eirini Christaki
@es
Eirini Christaki
@nl
Eirini Christaki
@sl
prefLabel
Eirini Christaki
@ast
Eirini Christaki
@en
Eirini Christaki
@es
Eirini Christaki
@nl
Eirini Christaki
@sl
P1053
E-5514-2013
P106
P1153
14043186000
P31
P3829
P496
0000-0002-8152-6367